Keane et al., 2021 - Google Patents
Neuro-Oncology AdvancesKeane et al., 2021
View PDF- Document ID
- 11238061583697035648
- Author
- Keane L
- Cheray M
- Saidi D
- Kirby C
- Friess L
- Gonzalez-Rodriguez P
- Gerdes M
- Grabert K
- McColl B
- Joseph B
- Publication year
External Links
Snippet
Background. Diffuse intrinsic pontine gliomas (DIPG), within diffuse midline gliomas are aggressive pediatric brain tumors characterized by histone H3-K27M mutation. Small- molecule inhibitors for the EZH2-H3K27 histone methyltransferase have shown promise in …
- 101700041849 EZH2 0 abstract description 164
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keane et al. | Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas | |
| Minata et al. | Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation | |
| Uehara et al. | Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease | |
| Tian et al. | TIMP1 derived from pancreatic cancer cells stimulates Schwann cells and promotes the occurrence of perineural invasion | |
| Song et al. | Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma | |
| Tao et al. | DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2 | |
| Fukaya et al. | MIF maintains the tumorigenic capacity of brain tumor–initiating cells by directly inhibiting p53 | |
| Mandinova et al. | The FoxO3a gene is a key negative target of canonical Notch signalling in the keratinocyte UVB response | |
| Yang et al. | DNMT1 controls LncRNA H19/ERK signal pathway in hepatic stellate cell activation and fibrosis | |
| Pei et al. | Colorectal cancer tumor cell-derived exosomal miR-203a-3p promotes CRC metastasis by targeting PTEN-induced macrophage polarization | |
| US11344601B2 (en) | Tumor microenvironment-related target TAK1 and application thereof in inhibition of tumor | |
| KR20140041770A (en) | Apoptosis-inducing agent | |
| Nam et al. | The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancer | |
| Guo et al. | TGF-β-mediated repression of MST1 by DNMT1 promotes glioma malignancy | |
| JP2007524622A (en) | Compositions and methods for restoring tumor cell sensitivity to anti-cancer therapy and inducing apoptosis | |
| Tao et al. | Lactate induced mesenchymal stem cells activation promotes gastric cancer cells migration and proliferation | |
| Chen et al. | Lentivirus mediated γ-interferon-inducible lysosomal thiol reductase (GILT) knockdown suppresses human glioma U373MG cell proliferation | |
| Dai et al. | Hedgehog-Gli1-derived exosomal circ-0011536 mediates peripheral neural remodeling in pancreatic cancer by modulating the miR-451a/VGF axis | |
| CN111073979A (en) | Gastric cancer treatment method for blocking CCL28 chemotactic pathway | |
| KR100856475B1 (en) | Antisense theraphy for hormone-regulated tumors | |
| Wu et al. | TTK inhibition alleviates Postinjury Neointimal formation and atherosclerosis | |
| JP4851451B2 (en) | Breast cancer-related gene ZNFN3A1 | |
| Watanabe et al. | Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma | |
| US11510911B2 (en) | Method for prediction of susceptibility to sorafenib treatment by using SULF2 gene, and composition for treatment of cancer comprising SULF2 inhibitor | |
| Ma et al. | MARK4 promotes the malignant phenotype of gastric cancer through the MAPK/ERK signaling pathway |